Invasive meningococcal disease (laboratory reports in England): January to March 2017

Health Protection Report
Volume 11 Number 23
30 June 2017
Laboratory confirmed cases of invasive meningococcal infection (England): January to March 2017

In England, the national Public Health England (PHE) Meningococcal Reference Unit (MRU) confirmed 266 cases of invasive meningococcal disease (IMD) between January and March 2017 [1]. IMD cases were 3% lower during these three months compared to 273 cases in the equivalent period in 2016 (table 1).

The distribution of meningococcal capsular groups causing IMD by age is summarised in table 2, with capsular group B (MenB) accounting for 55% (146/266) of all cases, followed by MenW (n=80, 30%), MenY (n=27, 10%), MenC (n=11, 4%), one capsular group E and one ungroupable.

The number of MenW cases confirmed between January and March 2017 increased by 11% from 72 cases in the same period in 2016 to 80. The number of MenC cases confirmed during this period in 2017 decreased by a 35% from 17 cases reported in the same period in 2016 to 11 and confirmed MenY decreased by 23% from 35 to 27 cases while confirmed cases of MenB were similar. There were no reported cases for capsular groups A, X and Z (table 1).

Between January and March 2017 MenB was responsible for the majority of IMD cases in infants (19/25, 76%) and toddlers (33/46, 72%) but, as expected, contributed to a lower proportion of cases in older age groups (table 2). The introduction of a routine national MenB immunisation programme for infants was announced in June 2015 [2] with immunisation of infants starting from 1 September 2015. Preliminary vaccine coverage estimates for those eligible for infant MenB immunisation are 95.8% for one dose, 93.5% for two doses and 87.9 for the booster dose by 18 months age (evaluated to the end of February 2017) [3]. The two-dose infant MenB schedule has been shown to be highly effective in preventing MenB disease in infants [4].

Almost half of the 80 MenW cases confirmed between January and March 2017 were in adults aged 65 years or older (44%, 35/80) followed by individuals aged 45 to 64 years (20%; 16/80). Infants and toddlers accounted for 20% (n=16) of MenW IMD and young adults aged between 15 and 24 years for 6.3% (n=5) of MenW cases in England. The increase in MenW cases, which has been previously reported [5,6], led to the introduction of MenACWY conjugate vaccine to the national immunisation programme in England [2,7]. MenACWY vaccine replaced the existing time-limited ‘freshers’ programme from August 2015 and was directly substituted for MenC vaccine in the routine adolescent schools programme (school year 9 or 10) from Autumn 2015. Preliminary coverage data for the first cohorts to be routinely offered MenACWY vaccine in schools from September 2015 (Year 9 and 10 in 2015/16) and evaluated up to the end of August 2016 was 84.1% (Year 9), 77.2% (Year 10) and 71.8% for the catch-up cohort (Year 11 in 2015/16) [8]. Vaccine coverage estimates for the first cohort through the GP based catch-up programme (individuals born from 1 September 1996 to 31 August 1997) and evaluated from August 2015 to end March 2017 was 38.9% and 33.0% for the second cohort, born 1 September 1997 to 31 August 1998, and evaluated from April 2016 to the end of March 2017 [9].

All teenagers born between 01/09/1998-31/08/1999 (2017 school leaver cohort) are now eligible for urgent catch-up with MenACWY vaccination. These young people should be invited
by their GP practice for vaccination. All teenage cohorts remain eligible for opportunistic MenACWY vaccination until the age of 25 and it is important that these teenagers continue to be encouraged to be immunised, particularly if they are entering Higher Educations Institutions. Early analysis of the MenACWY teenage vaccination programme has shown high effectiveness with no cases vaccinated under the current programme [11].

Table 1. Invasive meningococcal disease in England by capsular group and laboratory testing method: January – March 2017

<table>
<thead>
<tr>
<th>Capsular groups~</th>
<th>CULTURE AND PCR</th>
<th>CULTURE ONLY</th>
<th>PCR ONLY</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>Q1</td>
<td>Q1</td>
<td>Q1</td>
<td>Q1</td>
</tr>
<tr>
<td>C</td>
<td>3</td>
<td>4</td>
<td>23</td>
<td>31</td>
</tr>
<tr>
<td>W</td>
<td>14</td>
<td>13</td>
<td>9</td>
<td>49</td>
</tr>
<tr>
<td>Y</td>
<td>10</td>
<td>2</td>
<td>22</td>
<td>19</td>
</tr>
<tr>
<td>Other*</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>58</td>
<td>56</td>
<td>103</td>
<td>113</td>
</tr>
</tbody>
</table>

~ No cases of groups A, X, Z or ungrouped were confirmed during the periods summarised in the table.
* Other includes group E and ungroupable (ungroupable refers to invasive clinical meningococcal isolates that were non-groupable, while ungrouped cases refers to culture-negative but PCR screen (ctrA) positive and negative for the four genogroups [B, C, W and Y] routinely tested for).

Table 2. Invasive meningococcal disease in England by capsular group and age group at diagnosis: January – March 2017

<table>
<thead>
<tr>
<th>Age groups</th>
<th>Capsular Group~</th>
<th>Q3 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B</td>
<td>C</td>
</tr>
<tr>
<td>Total</td>
<td>146</td>
<td>11</td>
</tr>
</tbody>
</table>

~ No cases of groups A, X, Z or ungrouped were confirmed during the periods summarised in the table.
* Other includes group E and ungroupable (ungroupable refers to invasive clinical meningococcal isolates that were non-groupable, while ungrouped cases refers to culture-negative but PCR screen (ctrA) positive and negative for the four genogroups [B, C, W and Y] routinely tested for).
References

1. Data source: PHE Meningococcal Reference Unit, Manchester.
7. PHE website. Meningococcal ACWY (MenACWY) vaccination programme.
8. PHE (2016) HPR 10(44), 16 December 2016
9. PHE (2017) HPR 11(16), 28 April 2017
About Public Health England

Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner.

About Health Protection Report

*Health Protection Report* is a national public health bulletin for England and Wales, published by Public Health England. It is PHE’s principal channel for the dissemination of laboratory data relating to pathogens and infections/communicable diseases of public health significance and of reports on outbreaks, incidents and ongoing investigations.

Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG
Tel: 020 7654 8000  www.gov.uk/phe
Twitter: @PHE_uk  Facebook: www.facebook.com/PublicHealthEngland
Queries relating to this document should be directed to:
HIV and STI Department,
National Infection Service, PHE Colindale,
61 Colindale Avenue, London NW9 5EQ.
gumcad@phe.gov.uk

© Crown copyright 2017
You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL or email psi@nationalarchives.gsi.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published June 2017
PHE publications gateway number: 2017146